Acticor Biotech’s Post

Winston-Salem’s ProKidney Corp. says it’s made a $22.5 million deal to buy two buildings that will provide the therapeutics company with 180,000 feet of floor space. https://lnkd.in/egJgkB3D

Updated correlation matrix for PotlatchDeltic Corp( $PCH ), Beam Therapeutics( $BEAM ), Simon Property( $SPG ), Lee Enterprises( $LEE ), Patterson Companies( $PDCO ), Ross Stores( $ROST ), Carnival( $CCL ) and Allegheny Technologies( $ATI ) https://lnkd.in/gbVjSu69

Check pair correlations: Ventas( $VTR ), JM Smucker( $SJM ), Infocom( $IFFOF ), Johnson Controls( $JCI ), Humana( $HUM ), Devon Energy( $DVN ), State Street( $STT ), Beam Therapeutics( $BEAM ), Salesforce( $CRM ) and Genworth Financial( $GNW ) https://lnkd.in/gxESVPQF

Spartan Capital Securities, LLC Serves as Selling Group Member in Alpha Cognition, Inc.'s $4.454 Million Convertible Note and Warrants Bridge Financing   We are proud to announce that Spartan Capital Securities LLC participated as a selling group member in Alpha Cognition Inc.'s successful $4.454 million bridge financing. This financing, comprised of convertible notes and warrants, will support Alpha Cognition as they continue the commercialization of their novel therapies for neurodegenerative disorders, including Alzheimer’s disease.   The financing was led by The Benchmark Company, LLC., with their Kestrel Merchant Partners group responsible for sourcing and executing the transaction. Proceeds from the offering will be directed toward payer pricing, contracting work, and manufacturing efforts for Alpha Cognition’s recently approved drug, ZUNVEYL™.   This marks an important milestone in Alpha Cognition’s journey as they advance treatments that address critical unmet needs in the neurodegenerative disease space. We extend our sincere appreciation to Alpha Cognition’s management team for their partnership and collaboration.   As the biopharmaceutical market continues to evolve, Spartan Capital is dedicated to supporting companies poised for innovation and long-term success.   https://lnkd.in/enDJPEDh   #AlphaCognition #BridgeFinancing #NeurodegenerativeDisorders #ZUNVEYL #SpartanCapitalSecurities #InvestmentBanking #ConvertibleNotes #Warrants #Growth #Biopharma #CapitalMarkets #Partnerships #SuccessStory #HealthcareInnovation

Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) has announced the pricing of its US initial public offering (IPO) through its holding company, Anteris Technologies Global Corp (ATGC), a first step into an important market for the company. This follows the effective registration of the IPO with the US Securities and Exchange Commission on December 12, 2024. The IPO is part of the company’s strategy to expand its presence in global capital markets as it progresses its innovations in cardiovascular health. The IPO involves the offering of 14.8 million shares of common stock at a price of US$6.00 per share. Trading kicked off on the Nasdaq Global Market under the AVR ticker on December 13, with the offering expected to close on December 16, subject to customary conditions. ATGC has also granted underwriters a 30-day option to purchase up to an additional 2.22 million shares. More at #Proactive #ProactiveInvestors #ASX #AVR #Biotech #Nasdaq #AnterisTechnologies #CardiovascularHealth #IPOAnnouncement #NasdaqListing http://ow.ly/l4PX105RKNH

Scancell Holdings' interims 'highlight continued progress', says broker @scancellpharma #AIM #OTC #SCLP #SCNLF. Scancell Holdings PLC's (AIM:SCLP, OTC:SCNLF) interim results highlight continued progress in its cancer vaccine pipeline, with multiple data readouts expected before the end of 2025, according to Panmure Liberum. Reiterating its 'buy' advice and 24p a share price target, the brokerage noted that early data releases have helped to reduce some of the risks associated with the programmes. Panmure Liberum said that following a licence payment from Genmab, a December equity raise, and a larger-than-expected research and development tax credit, Scancell... http://ow.ly/7avh105Yihb

𝐈𝐃𝐑𝐱'𝐬 𝐜𝐨𝐦𝐩𝐥𝐞𝐭𝐢𝐨𝐧 𝐨𝐟 𝐚𝐧 𝐨𝐯𝐞𝐫𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞𝐝 𝐒𝐞𝐫𝐢𝐞𝐬 𝐁 𝐅𝐢𝐧𝐚𝐧𝐜𝐢𝐧𝐠 IDRx has announced the successful completion of an oversubscribed $120M Series B financing, led by RA Capital Management, Commodore Capital, and Blackstone Multi-Asset Investing. The funds will support the ongoing Phase 1/1b StrateGIST 1 study of IDRx's lead candidate, IDRX-42. Key highlights: • Fast Track designation granted by the U.S. FDA for IDRX-42. • Promising preliminary Phase 1 data, showing a 43% ORR in second-line GIST patients. • Strong backing from top-tier investors, including RA Capital, Andreessen Horowitz, and Merck KGaA. This milestone brings IDRx closer to its goal of transforming GIST treatment with precision therapies designed to address treatment resistance and adverse events. The company expresses its gratitude to the dedicated team, partners, and investors who continue to support its mission to elevate the standard of care for GIST patients. #Biotech #PrecisionMedicine #Oncology #GIST #ClinicalTrials 

Spartan Capital Securities, LLC Serves as Selling Group Member in Alpha Cognition, Inc.'s $4.454 Million Convertible Note and Warrants Bridge Financing   We are proud to announce that Spartan Capital Securities LLC participated as a selling group member in Alpha Cognition Inc.'s successful $4.454 million bridge financing. This financing, comprised of convertible notes and warrants, will support Alpha Cognition as they continue the commercialization of their novel therapies for neurodegenerative disorders, including Alzheimer’s disease.   The financing was led by The Benchmark Company, LLC., with their Kestrel Merchant Partners group responsible for sourcing and executing the transaction. Proceeds from the offering will be directed toward payer pricing, contracting work, and manufacturing efforts for Alpha Cognition’s recently approved drug, ZUNVEYL™.   This marks an important milestone in Alpha Cognition’s journey as they advance treatments that address critical unmet needs in the neurodegenerative disease space. We extend our sincere appreciation to Alpha Cognition’s management team for their partnership and collaboration.   As the biopharmaceutical market continues to evolve, Spartan Capital is dedicated to supporting companies poised for innovation and long-term success.   https://lnkd.in/eWpTgsG7   #AlphaCognition #BridgeFinancing #NeurodegenerativeDisorders #ZUNVEYL #SpartanCapitalSecurities #InvestmentBanking #ConvertibleNotes #Warrants #Growth #Biopharma #CapitalMarkets #Partnerships #SuccessStory #HealthcareInnovation

Summit Therapeutics #SMMT.US, which we positively ranked on the 12th March, was on Thursday up over 250% on positive clinical trial data. The purchases from the CFO and Co-CEO that triggered our positive recommendation have been highly profitable. Learn more: https://smartinsider.com/ #SummitTherapeutics #SMMT #SMMTUS #USstockmarket #smartinsider #insidertrading #equities #alternativedata #trading #investing #investment #insiderdeals #insidertransaction #stockmarket #stockmarkets #investmentmanagement #portfoliomanagement #portfoliomanager #investmentstrategy #altdata

J&J’s CAR-T Partner Legend Biotech Reportedly Receives Buyout Offer CAR-T specialist Legend Biotech has reportedly received a takeover bid and has tapped Centerview Partners as a financial adviser to evaluate its options, StreetInsider reports, citing an unnamed source. Legend, for its part, declined to comment on market rumors. Legend rose to fame through a 2017 collaboration with Johnson & Johnson on the BCMA CAR-T therapy Carvykti. The cell therapy’s remarkable efficacy in multiple myeloma has prompted J&J to peg its peak sales potential at above $5 billion. Given the two companies’ existing relationship, it’s possible J&J may be interested in acquiring its partner. https://lnkd.in/gqcqxBnq #aspenalert #biotech #bioprocess